5[1]Goto Y, Baba S, Nakagawa S, et al. A study of usefulness of an α-glucosidase inhibitor, AO-128, in the treatment period of NIDDM-clinical phase Ⅲ,double-blind,intergroup comparative study. J Clin Experiment Med, 1992, 160(12): 943
6[2]Mimura K, Umeda F. A study of clinical efficacy of long-term AO-128 treatment in 72 patients with NIDDM . J Clin Experiment Med, 1992, 69(3): 267
7[3]Odaka H, Miki N. Effects of a disaccharidase inhibitor, AO-128, on postprandial hyperglycemia in rats. The Journal of Japanese Society of Nutrition and Food Science, 1992, 45(1): 27
8GASTER B, HISCH IB. The effect of improved glycemic control on complication in type 2 diabets[J]. Arch Intern Med, 1998,158:134-141.
9ALAN D. Glycosidase inhibitors as antivival and/or antitumor agents[J]. Cell Biology, 1991,2:309-313.
